POAI [NASD]
Predictive Oncology Inc.
Index- P/E- EPS (ttm)-0.30 Insider Own1.00% Shs Outstand65.83M Perf Week-6.07%
Market Cap32.42M Forward P/E4.13 EPS next Y0.10 Insider Trans94.34% Shs Float63.42M Perf Month8.71%
Income-19.10M PEG- EPS next Q-0.04 Inst Own6.30% Short Float0.29% Perf Quarter-55.58%
Sales1.50M P/S21.61 EPS this Y83.80% Inst Trans-0.52% Short Ratio0.18 Perf Half Y-56.60%
Book/sh0.56 P/B0.74 EPS next Y225.00% ROA-39.90% Target Price4.42 Perf Year-65.86%
Cash/sh0.32 P/C1.29 EPS next 5Y- ROE-42.90% 52W Range0.25 - 1.47 Perf YTD-56.60%
Dividend- P/FCF- EPS past 5Y56.50% ROI-49.00% 52W High-71.83% Beta1.41
Dividend %- Quick Ratio9.60 Sales past 5Y25.50% Gross Margin65.70% 52W Low66.17% ATR0.04
Employees30 Current Ratio9.80 Sales Q/Q0.00% Oper. Margin- RSI (14)46.66 Volatility8.00% 11.77%
OptionableNo Debt/Eq0.00 EPS Q/Q51.90% Profit Margin- Rel Volume0.16 Prev Close0.41
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.04M Price0.41
Recom2.00 SMA200.59% SMA50-17.79% SMA200-52.89% Volume166,513 Change1.13%
May-18-22 05:15PM  
May-16-22 08:55AM  
May-12-22 05:15PM  
Apr-26-22 08:30AM  
Mar-31-22 05:25PM  
Mar-24-22 08:30AM  
Jan-27-22 07:30AM  
Jan-13-22 08:30AM  
Dec-27-21 05:10PM  
Dec-22-21 12:00PM  
Dec-21-21 08:30AM  
Dec-07-21 08:30AM  
Dec-01-21 08:30AM  
Nov-10-21 05:15PM  
Nov-08-21 03:00PM  
Oct-19-21 08:30AM  
Sep-15-21 08:30AM  
Aug-18-21 01:45PM  
Aug-11-21 05:15PM  
08:30AM  
Aug-05-21 10:39AM  
Aug-03-21 08:30AM  
Jun-22-21 08:30AM  
Jun-18-21 09:30AM  
Jun-14-21 09:30AM  
Jun-02-21 08:30AM  
May-20-21 08:30AM  
May-12-21 05:20PM  
Apr-27-21 08:30AM  
Apr-21-21 08:17AM  
Mar-23-21 08:30AM  
Mar-15-21 05:15PM  
Mar-08-21 08:30AM  
Feb-24-21 08:30AM  
Feb-23-21 05:30PM  
Feb-18-21 09:00AM  
Feb-17-21 08:30AM  
Feb-16-21 05:00PM  
Feb-11-21 12:30AM  
Feb-08-21 08:30AM  
Feb-02-21 12:00PM  
08:30AM  
Jan-28-21 08:30AM  
Jan-26-21 09:00PM  
Jan-22-21 08:00AM  
Jan-21-21 05:25PM  
Jan-19-21 08:00AM  
Jan-14-21 08:30AM  
Jan-12-21 05:15PM  
Jan-08-21 09:00AM  
Jan-06-21 08:30AM  
Jan-05-21 08:30AM  
Dec-29-20 05:15PM  
Dec-09-20 08:30AM  
Dec-02-20 08:00AM  
Nov-16-20 05:20PM  
Oct-27-20 08:30AM  
Oct-06-20 08:30AM  
Oct-02-20 12:14PM  
Sep-22-20 05:10PM  
Sep-01-20 05:15PM  
Aug-20-20 08:30AM  
Aug-18-20 08:30AM  
Aug-14-20 08:30AM  
Aug-13-20 05:10PM  
Aug-11-20 08:30AM  
Aug-05-20 09:00AM  
Jul-14-20 08:30AM  
Jul-07-20 08:15AM  
Jun-29-20 04:30PM  
Jun-18-20 08:30AM  
Jun-08-20 04:15PM  
Jun-02-20 08:30AM  
May-14-20 08:30AM  
May-07-20 08:00AM  
May-06-20 08:30AM  
Apr-22-20 05:00PM  
08:30AM  
Apr-01-20 08:45AM  
Mar-31-20 08:30AM  
Mar-23-20 08:00AM  
Mar-16-20 09:00AM  
Mar-12-20 08:30AM  
Mar-02-20 08:30AM  
Feb-21-20 08:30AM  
Feb-07-20 02:05PM  
Feb-05-20 08:30AM  
Jan-24-20 12:30PM  
Jan-06-20 09:00AM  
Dec-17-19 08:30AM  
Dec-09-19 08:30AM  
Dec-05-19 08:30AM  
Nov-25-19 08:30AM  
Nov-20-19 08:30AM  
Nov-19-19 08:30AM  
Nov-15-19 05:10PM  
Nov-07-19 08:30AM  
Nov-06-19 08:30AM  
Oct-31-19 08:30AM  
08:30AM  
Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HANDLEY DANIEL EDirectorMay 26Buy0.372,55095549,666May 27 11:35 AM
HANDLEY DANIEL EDirectorMay 25Buy0.352,80098047,116May 25 12:32 PM
ENGLE J MELVILLEDirectorMay 24Buy0.37159,50059,334203,393May 24 02:31 PM
Nuzum Charles Lee SrDirectorMay 20Buy0.31200,00062,320286,164May 20 02:24 PM
MYERS ROBERT LCHIEF FINANCIAL OFFICERMay 20Buy0.3016,1254,88939,336May 20 02:22 PM
MYERS ROBERT LChief Financial OfficerSep 23Option Exercise1.1333,33437,66733,411Sep 24 04:07 PM